Research partnerships

Earendil Labs announced a research collaboration with Genentech (Roche Group) to discover bispecific antibodies in oncology using Earendil's AI-driven biologics platform; Earendil reports $55 million upfront and potential value above $1.5 billion.

Partners: Earendil Labs

AbbVie and Iambic announced a multi-year collaboration using Iambic's AI discovery platform to find small-molecule candidates in immunology, neuroscience and oncology.

Partners: Iambic

A collaboration to test Anthropic's Claude Science on chosen R&D problems and use Anthropic models for AI-assisted software engineering.

Partners: Anthropic

BenchSci announced a two-year enterprise agreement for argenx scientists to use EMET, its agentic research environment, in preclinical, computational and drug development workflows; argenx is quoted as testing whether it can accelerate preclinical development.

Partners: BenchSci

Noetik says it met the first milestone of its five-year licensing agreement with GSK (announced January 2026, $50 million upfront capital and near-term milestones) and that GSK teams are using its OCTO-VC models for virtual cell experiments, patient stratification and H&E data enrichment.

Partners: Noetik

A lab-in-the-loop system built with AWS that gives discovery AI agents shared memory of past experiments. Sanofi aims to halve the number of molecules needing wet-lab validation.

Partners: AWS

Nucleai says it has used AI to analyze H&E and IHC whole-slide images from several Gilead oncology clinical studies in support of Gilead's ADC clinical programs, generating candidate spatial biomarkers.

Partners: Nucleai

Recursion reports that a joint Recursion-Genentech team identified and validated a first target from an AI-driven neuroscience map, now advancing into a joint small-molecule early discovery program.

Partners: Recursion

Relation announced a strategic research collaboration with GSK to generate large-scale human cellular perturbation data and deploy it into models including MORGAN, its cellular biology foundation model; Relation reports up to $110 million in upfront and success-based milestone payments.

Partners: Relation

Incyte's quarterly report for the period ended 30 June 2026 says that in May 2026 the company entered a license, research and collaboration agreement with Genesis Molecular AI covering the building and deployment of artificial intelligence to accelerate discovery of novel molecules. Under the agreement, Incyte will identify targets and Genesis will use the Genesis Exploration of Molecular Space artificial intelligence platform to identify molecular structures for each target. The filing says Incyte paid Genesis $120.0 million, made up of an $80.0 million upfront payment and a $40.0 million equity investment.

Partners: Genesis Molecular AI

Incyte's second-quarter 2026 earnings release says that in May the company expanded its use of artificial intelligence across discovery and development, including a strategic collaboration with Edison Scientific to employ Edison's AI scientist Kosmos.

Partners: Edison Scientific

A multi-year collaboration, first signed in December 2023, that uses Aqemia's generative AI and physics-based platform to design small molecules. It was expanded in July 2026 with a new target nomination.

Partners: Aqemia

Chai Discovery announced a collaboration agreement giving argenx access to its AI platform to apply de novo antibody discovery across therapeutic targets.

Partners: Chai Discovery

Chai Discovery announced a collaboration giving Novartis access to Chai's AI models, including Chai-3, for antibody discovery across multiple targets.

Partners: Chai Discovery

A collaboration using Insilico's generative AI Pharma.AI platform to find drug candidates across Takeda's therapeutic areas.

Partners: Insilico Medicine

Bayer and Iambic announced a drug-discovery collaboration in which Bayer will use Iambic's AI-driven platform. The collaboration is focused on small-molecule discovery.

Partners: Iambic

A multi-year deal to co-develop biopharma AI agents with Owkin, backed by a five-year licence to Owkin's K Pro AI scientist.

Partners: Owkin

Alnylam and Inceptive Nucleics announced a strategic collaboration, valued at up to $2B with upfront consideration of $30M, pairing Alnylam's RNAi platform and proprietary siRNA data with Inceptive's foundation models and AI expertise to accelerate nucleic-acid drug design.

Partners: Inceptive Nucleics, Inc.

Atinary's machine-learning experiment optimizer is being built into Takeda discovery workflows to speed up reaction and process optimization.

Partners: Atinary, AWS

UCB and the University of Southampton announced DARC, a three-year effort to build an end-to-end in-silico platform for therapeutic antibody design. UCB's head of UK research says the partnership strengthens UCB's position in AI-enabled antibody design.

Partners: University of Southampton

TriNetX and Regeneron announced a collaboration giving Regeneron access to TriNetX de-identified electronic health records; the release says the growing database will drive drug discovery and development and empower AI training algorithms for digital health solutions.

Partners: TriNetX

insitro says BMS nominated two more ALS targets identified via insitro's AI-driven Virtual Human platform, expanding their collaboration.

Partners: insitro

Merck co-developed KERMT with NVIDIA, a deep-learning model trained on millions of molecules to predict compound properties for drug discovery.

Partners: NVIDIA

Sandoz's 2025 integrated report says the company is part of the EU-funded DRAIGON research consortium, which uses AI and genomics to predict resistance and support better treatment decisions, as one of its antimicrobial-resistance research projects.

Partners: DRAIGON consortium

Merck and Mayo Clinic agreed that Merck will use Mayo Clinic Platform's de-identified multimodal clinical and genomic data to validate AI models, including virtual-cell work, for target identification and early development choices.

Partners: Mayo Clinic

A multi-year partnership that gives Takeda access to Iambic's AI discovery tools, including the NeuralPLexer protein-ligand model, initially for oncology and GI/inflammation programs.

Partners: Iambic Therapeutics

AstraZeneca bought Modella AI, following a 2025 collaboration, to bring its pathology foundation models and AI agents in-house for oncology R&D, including biomarker and targeted-therapy work.

Partners: Modella AI

Lilly and NVIDIA are setting up a joint Bay Area AI lab for drug discovery, with up to $1 billion invested over five years in people, infrastructure and compute.

Partners: NVIDIA

Pfizer and Boltz agreed to tune Boltz's open biomolecular foundation models on Pfizer's historical data into exclusive models and roll them out to Pfizer scientists for small-molecule and biologics design.

Partners: Boltz

Bayer announced a three-year collaboration and said it will integrate Cradle's generative AI platform into existing R&D workflows for antibody lead generation and optimization. Bayer says it selected Cradle after a successful proof of concept.

Partners: Cradle

GSK and the Fleming Initiative announced six Grand Challenges, funded from GSK's GBP 45 million pledge, that use technologies including advanced AI. One programme will build an AI/ML model to design antibiotics for multi-drug-resistant Gram-negative bacteria, and another will build AI models that predict how drug-resistant pathogens emerge and spread.

Partners: Fleming Initiative

Sequantrix announced an agreement with argenx for the use of its AI-driven DiseaseDecoder technology, a computational framework for identifying and evaluating targets.

Partners: Sequantrix

A second multi-year deal applying Nabla Bio's generative Joint Atomic Model to design antibodies and other protein drugs for Takeda's early programs.

Partners: Nabla Bio

Takeda joined a federated effort to fine-tune the OpenFold3 structure-prediction model on proprietary protein-ligand data without sharing the data itself.

Partners: Apheris, AlQuraishi Lab (Columbia)

Merck signed a deal worth up to $349 million under which Variational AI tunes its generative chemistry platform on Merck data to design small molecules for two Merck-chosen targets.

Partners: Variational AI

Revolution Medicines said it had recently announced a drug-discovery collaboration with Iambic Therapeutics in which Iambic will use its AI capabilities to generate customized models trained on Revolution Medicines' proprietary data. The release says the collaboration aims to enhance lead discovery and optimization against current and new drug targets.

Partners: Iambic Therapeutics

Otsuka Pharmaceutical, K.K. eMind and Tohoku University announced Phase II of the Epilepsy Smart Medical collaborative research project. The release says the project applies eMind's AI prediction technology to epilepsy and that its objective is to support patients through digital devices and AI. Otsuka joined Phase II in April 2025.

Partners: K.K. eMind, Tohoku University

UC Santa Cruz reports that argenx and Unnatural Products entered a multi-target collaboration using UNP's platform, which combines AI-guided compound design, parallel synthesis and direct-to-biology screening, with up to about $1.5 billion in potential payments to UNP.

Partners: Unnatural Products

A collaboration with NVIDIA to build custom AI models and agents for early research and clinical development on the Gefion AI supercomputer.

Partners: NVIDIA, Danish Centre for AI Innovation (DCAI)

Novo worked with Columbia University and AWS inside the OpenFold consortium to train the OpenFold3 protein-structure model.

Partners: AWS, Columbia University, OpenFold Consortium

Merck KGaA and imec announced a partnership to develop a modular MPS-on-a-chip platform intended to simulate human body responses and provide high-quality training data for AI models in drug discovery.

Partners: imec

Incyte's first-quarter 2025 update says that in February 2025 the company and Genesis Therapeutics entered a strategic collaboration on the research, discovery and development of novel small-molecule medicines, initially for targets selected by Incyte. The same update says Incyte receives exclusive rights to develop and commercialize collaboration products leveraged through Genesis's GEMS artificial intelligence platform.

Partners: Genesis Therapeutics

AstraZeneca agreed with Tempus and Pathos to build a large multimodal oncology foundation model from clinical and molecular data to support its cancer R&D.

Partners: Tempus, Pathos

UCB researchers describe FLuID, a federated-learning method for drug discovery, and say that collaborating pharmaceutical companies have improved predictions of how chemical compounds interact with the human body.

Truveta says its member health systems will partner with the Regeneron Genetics Center to sequence up to ten million exomes, and that the de-identified sequencing data added to Truveta Data will let research develop AI that accelerates drug discovery. Truveta reports a $119.5 million Regeneron investment.

Partners: Truveta

UCB and XtalPi announced a license under which Ailux Biologics grants UCB a non-exclusive license to XtalFold, which the release calls a proprietary AI-based software suite for structural insights in biologics discovery and engineering.

Partners: XtalPi, Ailux Biologics

An expanded collaboration using Valo's human-data and AI platform to discover up to 20 drug programs in obesity, type 2 diabetes and cardiovascular disease.

Partners: Valo Health

PostEra extended its machine-learning drug discovery alliance with Pfizer, adding more small-molecule targets and a new antibody-drug conjugate payload track, for a total potential value of about $610 million.

Partners: PostEra

Gilead and Terray announced a multi-target collaboration using Terray's tNova platform, which combines high-throughput chemistry with a generative AI discovery engine.

Partners: Terray Therapeutics

Generate:Biomedicines announced a multi-target collaboration with Novartis using Generate's generative AI platform to discover protein therapeutics; Generate reports $65 million upfront consideration and potential value above $1 billion.

Partners: Generate:Biomedicines

Gilead and Genesis Therapeutics announced a collaboration using Genesis's GEMS AI platform to generate and jointly optimize molecules against selected targets.

Partners: Genesis Therapeutics

A three-year extension of a collaboration that applies human genetics and machine learning to drug discovery and development.

Partners: Genomics plc

Bayer and Aignostics announced a multi-year collaboration to identify novel cancer targets with AI models on multimodal patient data, and to develop AI and machine-learning pathology algorithms that connect pathology and clinical data for trial patient identification, stratification and selection.

Partners: Aignostics

VantAI announced a collaboration with BMS using its generative AI and geometric deep learning to identify molecular glues, with up to $674 million in milestones.

Partners: VantAI

Isomorphic Labs announced a strategic research collaboration with Novartis to discover small-molecule therapeutics against three undisclosed targets using Isomorphic's AI drug design platform.

Partners: Isomorphic Labs

Isomorphic Labs agreed a multi-target research deal with Lilly to find small molecules using its AI platform, with $45 million upfront and up to $1.7 billion in milestones.

Partners: Isomorphic Labs

Teva and Biolojic announced an exclusive license to develop a potential antibody therapy for atopic dermatitis and asthma. The release describes Biolojic as a company that uses computational biology and artificial intelligence to design antibodies.

Partners: Biolojic Design

AbbVie and BigHat announced a research collaboration using BigHat's AI/ML-guided Milliner platform to discover next-generation antibodies in oncology and neuroscience, with a $30 million upfront payment.

Partners: BigHat Biosciences

Bayer and Recursion focused their research collaboration on precision oncology, using Recursion's AI-guided drug discovery platform. They may initiate up to seven oncology programs, and Recursion is eligible for up to $1.5 billion plus royalties on net sales.

Partners: Recursion

Otsuka Pharmaceutical and Shape TX announced a multi-target collaboration to develop intravitreally delivered AAVs for ocular diseases. The release describes Shape TX's AI-driven AAVid platform as combining screening of billions of AAV variants with machine learning to identify novel capsids, and says Shape TX is eligible for payments potentially exceeding $1.5 billion.

Partners: Shape TX

Teva describes AION Labs, the venture studio it formed with AstraZeneca, Merck, Pfizer and other partners, and says DenovAI has developed an AI-physics platform to discover antibodies and proteins for conditions such as cancer and neurodegenerative illness.

Partners: AION Labs

An agreement to explore IBM's generative AI and quantum computing for mRNA and lipid nanoparticle research.

Partners: IBM

UCB and Aitia announced an early drug-discovery collaboration to discover and validate targets and drug candidates for Huntington's disease. The release describes Aitia as a leader in Causal AI and digital twins for discovering drugs.

Partners: Aitia

BioNTech and InstaDeep announced an agreement under which BioNTech will acquire InstaDeep, described as a technology company in artificial intelligence and machine learning. The release says BioNTech-trained AI and machine-learning models are planned to be embedded across discovery platforms, and that the companies have jointly developed multiple end-to-end AI-based applications. Closing was still expected in the first half of 2023.

Partners: InstaDeep

Roivant said its subsidiaries Proteovant Therapeutics and VantAI had entered research collaborations on protein degraders and E3 ligase platforms. VantAI and Janssen Pharmaceutica will use VantAI's geometric deep learning platform, which generates degrader candidates for two disease targets. VantAI and Boehringer Ingelheim will use that platform to design degrader molecules. The Proteovant collaboration with Blueprint Medicines brings in VantAI's artificial intelligence technologies for degrader generation and optimization. The release says the Blueprint, Janssen and Boehringer Ingelheim collaborations include aggregate contingent milestone payments of over $1 billion as well as product royalties.

Partners: Janssen Pharmaceutica, Boehringer Ingelheim, Blueprint Medicines

Shionogi and NEC announced a strategic research collaboration for a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary the release describes as specializing in artificial-intelligence-driven biotechnology, is also participating. The release says the companies will accelerate progress toward the vaccine by combining Shionogi's infectious-disease discovery capability with NEC's expertise in artificial intelligence.

Partners: NEC, NEC OncoImmunity

BioNTech and InstaDeep announced a computational method that analyzes sequencing data and predicts high-risk SARS-CoV-2 variants. The Early Warning System, developed in the collaboration, is based on artificial-intelligence immune-escape and fitness metrics. The release says that during a trial period the system identified more than 90 percent of WHO-designated variants on average two months in advance.

Partners: InstaDeep

Hengrui announced a strategic collaboration with Iktos, which it describes as a French company that develops artificial-intelligence platforms for new-drug design. The page says Hengrui will use Iktos's AI-based de novo design software Makya to accelerate small-molecule discovery and lead-compound optimization.

Partners: Iktos

Shionogi said it had concluded a research collaboration with InveniAI on AI-powered multi-target drug discovery in psycho-neurological disease using AlphaMeld. The release describes AlphaMeld as an AI drug-discovery platform that identifies multiple targets related to a specific disease and the mechanisms for treating those diseases.

Partners: InveniAI

Roivant said it had entered a definitive agreement to acquire Silicon Therapeutics. The release says physics-based approaches at Silicon Therapeutics are to be integrated with machine-learning approaches at VantAI, including the use of computational-physics simulations as training data for VantAI's degrader-specific deep learning models. The agreement was still subject to customary closing conditions.

Partners: Silicon Therapeutics

UCB and Microsoft announced a multi-year collaboration combining Microsoft's computational services, cloud and artificial intelligence with UCB's drug discovery and development capabilities. The release says the platform can support UCB's scientists.

Partners: Microsoft

BioNTech and InstaDeep announced a multi-year collaboration to apply artificial intelligence and machine learning to novel immunotherapies for cancers and infectious diseases. They said they will form a joint AI Innovation Lab in London and Mainz covering drug discovery and design, protein engineering, manufacturing and supply-chain optimization. The release also says BioNTech plans to use AI and machine-learning applications to optimize manufacturing and supply-chain processes.

Partners: InstaDeep

Shionogi announced the Innovation Centre in Digital Molecular Technologies, an open consortium with the University of Cambridge and AstraZeneca for automated and digitalized chemical synthesis of molecules such as drugs. The release says the consortium aims to innovate chemistry practice by integrating high-throughput synthesis, analytics, chemical informatics, machine learning, robotics and reaction engineering.

Partners: University of Cambridge, AstraZeneca

Hansoh and Atomwise announced an expansion of their strategic partnership for AI-accelerated drug discovery, after a first hit-discovery collaboration that identified and experimentally confirmed novel hit compounds for a challenging oncology target. The release says the collaboration began in November 2019 and that Atomwise used its AtomNet AI technology to screen a virtual library of over 12 billion compounds, finding 200 predicted candidates with target specificity in two weeks from a single virtual screen.

Partners: Atomwise

Galderma, the European Society for Dermatological Research, LEO Pharma and Celgene announced they had joined forces to found the Skin Science Foundation. The release says the foundation will use big data and machine learning on everyday data from blood tests, multi-omics analyses and wearable devices for a personalised approach to skincare.

Partners: European Society for Dermatological Research, LEO Pharma, Celgene